Dr. Gurkamal Singh Chatta, MD

Dr. Chatta practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. Chatta's NPI, 1114999083, was assigned on February 6, 2006. Dr. Chatta holds New York license 284329.

Dr. Chatta's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. Chatta's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. Chatta is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center. Dmand AI also links Dr. Chatta to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chatta practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Chatta's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Chatta's licenses on file in 3 states: New York, Pennsylvania and Washington.

CMS data shows 203 Medicare services from Dr. Chatta across 3 procedure codes in 2024, all of them office visits, for 99 Medicare patients. Medicare paid $14,600 for them.

CMS counts 99 Medicare patients who saw Dr. Chatta in 2024. The largest group is 65 to 74, with 43 patients. 75% of them have cancer, and 75% have high blood pressure. 15% are also on Medicaid. Their average risk score is 2.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chatta's median patient age at 74, with 11% women.

In 2024, Dr. Chatta wrote 64 Medicare Part D claims for 40 patients. 97% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $86 in total drug cost. In 2023, CMS named 22 claims across 1 drug.

Dr. Chatta accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chatta as offering telehealth.

Dmand AI links 38 papers to Dr. Chatta, published from 2012 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Urinary Bladder Neoplasms, Prostatic Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Dr. Chatta has published most often in bioRxiv. Dr. Chatta's most frequent co-authors are Khurshid Ahad Guru, MD, Igor Puzanov, MD and Dharmesh Gopalakrishnan, MD.

Dmand AI links Dr. Chatta to 8 clinical trials, 3 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Transitional Cell. Roswell Park Cancer Institute sponsors the most, 3. Open Payments lists research payments to Dr. Chatta that name 1 trial.

CMS Open Payments shows 48 general payments to Dr. Chatta from 15 drug and device companies from 2016 to 2024. Education make up the largest share, 40% of the total. AstraZeneca Pharmaceuticals LP paid the most, $12,960. It also lists 2 research payments totaling $720 from 2024 to 2025, naming 1 clinical trial.